Oct 4 (Reuters) - Kindred Biosciences Inc
* Kindred Biosciences receives approval of effectiveness technical section from fda for zimeta new animal drug application
* Kindredbio is in process of responding to first round of review by fda on safety technical section
* Kindred Biosciences Inc says expects approval of Zimeta in first half of 2017 if FDA review process is rapid Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.